Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
ApexOnco Front Page
Recent articles
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Nenocorilant features among the latest industry projects newly into phase 1.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Two new PD-(L)1 x VEGF projects have entered the clinic.
The private ADC company is being wound down.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
